Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA
Spruce Biosciences has swept away 55% of its employees. The biotech took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for accelerated approval in 2026.
Spruce Biosciences has swept away 55% of its employees. The biotech took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for accelerated approval in 2026.
